This will affect thousands of patients.
Starting from January 1, a crucial medication relied upon by numerous patients to manage breathing conditions will vanish from pharmacy shelves, sparking concern among doctors regarding potential delays in patients transitioning to alternatives and obtaining insurance coverage for the new medication.
The manufacturer, GSK, has announced the discontinuation of Flovent, a well-known branded asthma inhaler. Instead, they will introduce an “authorized generic” version identical in composition but lacking the original branding. Physicians, while assuring the effectiveness of the authorized generic, express worry as it doesn’t seem to enjoy the same extensive insurance coverage. This shift may force patients to secure new prescriptions and navigate coverage complexities, especially amidst the peak of the respiratory virus season.
Dr. Robyn Cohen, a pediatric pulmonologist at Boston Medical Center, emphasized the immense impact of Flovent’s discontinuation, a medication long favored by pediatricians for daily preventive use in asthma treatment.
Medical professionals advise patients to take proactive measures in securing their medication before the transition and advocacy groups have been actively disseminating this information. However, the underlying reasons behind Flovent’s disappearance and the insurance coverage disparity for its seemingly identical replacement delve into the intricate landscape of American healthcare and drug pricing.
A GSK spokeswoman attributed this change to their commitment to patient welfare, highlighting the introduction of authorized generics in the past and the subsequent discontinuation of branded versions in the U.S. She stated that these generics aim to offer potentially more affordable alternatives for patients.
Yet, industry observers note a timing correlation between GSK’s switch and Medicaid rebate policy alterations. The removal of the rebate cap for medicines with significant price hikes over time could lead to substantial penalties for companies like GSK. This alteration, effective January 1, would hold pharmaceutical companies liable to sell certain drugs to Medicaid at a loss if the rebate surpasses the drug’s price.
To navigate these impending changes and avoid potential losses, GSK’s move to introduce authorized generics, despite pricing them lower than the branded version, faces challenges. Major pharmacy benefit managers like CVS Caremark are favoring other branded inhalers over GSK’s authorized generics due to perceived cost differences based on net prices and manufacturer rebates.
This evolving landscape in drug pricing and insurance coverage poses significant challenges for patients and manufacturers alike, underscoring the complexities entrenched within the American healthcare system.
Discussion about this post